182 related articles for article (PubMed ID: 33782625)
1. Overexpression of MYBL2 predicts poor prognosis and promotes oncogenesis in endometrial carcinoma.
Le L; Luo J; Wu H; Chen L; Tang X; Fu F
Eur J Histochem; 2021 Mar; 65(2):. PubMed ID: 33782625
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of MYBL2 promotes proliferation and migration of non-small-cell lung cancer via upregulating NCAPH.
Xiong YC; Wang J; Cheng Y; Zhang XY; Ye XQ
Mol Cell Biochem; 2020 May; 468(1-2):185-193. PubMed ID: 32200471
[TBL] [Abstract][Full Text] [Related]
3. MYBL2 Is Targeted by miR-143-3p and Regulates Breast Cancer Cell Proliferation and Apoptosis.
Chen J; Chen X
Oncol Res; 2018 Jul; 26(6):913-922. PubMed ID: 29268817
[TBL] [Abstract][Full Text] [Related]
4. MiR-29a-5p inhibits proliferation and invasion and induces apoptosis in endometrial carcinoma via targeting TPX2.
Jiang T; Sui D; You D; Yao S; Zhang L; Wang Y; Zhao J; Zhang Y
Cell Cycle; 2018; 17(10):1268-1278. PubMed ID: 29888640
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of TICRR and PPIF confer poor prognosis in endometrial cancer identified by gene co-expression network analysis.
Yang L; Cui Y; Sun X; Wang Y
Aging (Albany NY); 2021 Jan; 13(3):4564-4589. PubMed ID: 33495413
[TBL] [Abstract][Full Text] [Related]
6. [High expression of MYBL2 promotes progression and predicts a poor survival outcome of prostate cancer].
Yang M; Zhu X; Shen Y; He Q; Qin Y; Shao Y; Yuan L; Ye H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Aug; 42(8):1109-1118. PubMed ID: 36073208
[TBL] [Abstract][Full Text] [Related]
7. Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma.
Zhang X; Lv QL; Huang YT; Zhang LH; Zhou HH
J Exp Clin Cancer Res; 2017 Aug; 36(1):105. PubMed ID: 28784180
[TBL] [Abstract][Full Text] [Related]
8. miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer.
He Z; Xu H; Meng Y; Kuang Y
Biomed Pharmacother; 2017 Apr; 88():902-910. PubMed ID: 28178620
[TBL] [Abstract][Full Text] [Related]
9. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma.
Guan Z; Cheng W; Huang D; Wei A
Curr Res Transl Med; 2018 Mar; 66(1):27-32. PubMed ID: 29274707
[TBL] [Abstract][Full Text] [Related]
10. LncRNA LOXL1-AS1 regulates the tumorigenesis and development of lung adenocarcinoma through sponging miR-423-5p and targeting MYBL2.
Li W; Zhang B; Jia Y; Shi H; Wang H; Guo Q; Li H
Cancer Med; 2020 Jan; 9(2):689-699. PubMed ID: 31758653
[TBL] [Abstract][Full Text] [Related]
11. MYBL2 regulates de novo purine synthesis by transcriptionally activating IMPDH1 in hepatocellular carcinoma cells.
Zhao JZ; Wang W; Liu T; Zhang L; Lin DZ; Yao JY; Peng X; Jin G; Ma TT; Gao JB; Huang F; Nie J; Lv Q
BMC Cancer; 2022 Dec; 22(1):1290. PubMed ID: 36494680
[TBL] [Abstract][Full Text] [Related]
12. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
13. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
[TBL] [Abstract][Full Text] [Related]
14. A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer.
Liu Q; Guo L; Qi H; Lou M; Wang R; Hai B; Xu K; Zhu L; Ding Y; Li C; Xie L; Shen J; Xiang X; Shao J
Cell Death Dis; 2021 Jul; 12(7):683. PubMed ID: 34234118
[TBL] [Abstract][Full Text] [Related]
15. MYBL2 is a Potential Prognostic Marker that Promotes Cell Proliferation in Gallbladder Cancer.
Liang HB; Cao Y; Ma Q; Shu YJ; Wang Z; Zhang F; Ye YY; Li HF; Xiang SS; Song XL; Xu Y; Zhang YC; Bao RF; Yuan RY; Zhang YJ; Hu YP; Jiang L; Li ML; Wang XA; Wu XS; Wu WG; Zhao S; Fand Y; Cui XP; Lu YS; Zhou J; Zheng L; Gong W; Liu YB
Cell Physiol Biochem; 2017; 41(5):2117-2131. PubMed ID: 28427077
[TBL] [Abstract][Full Text] [Related]
16. MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3.
Liu W; Shen D; Ju L; Zhang R; Du W; Jin W; Xiong K; Wang G; Qian K; Zhang Y; Xiao Y; Wang X
Oncogene; 2022 Oct; 41(41):4606-4617. PubMed ID: 36071275
[TBL] [Abstract][Full Text] [Related]
17. A novel DNA methylation 10-CpG prognostic signature of disease-free survival reveal that MYBL2 is associated with high risk in prostate cancer.
Hou X; Zhang Y; Han S; Hou B
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1107-1119. PubMed ID: 33073649
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA LINC01139 promotes the progression of hepatocellular carcinoma by upregulating MYBL2 via competitively binding to miR-30 family.
Li ZB; Chu HT; Jia M; Li L
Biochem Biophys Res Commun; 2020 May; 525(3):581-588. PubMed ID: 32115147
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of ESPL1 is associated with poor prognostic outcomes in endometrial cancer.
Yang Y; Sheng Y; Zheng J; Ma A; Chen S; Lin J; Yang X; Liang Y; Zhang Y; Zheng X
Biomarkers; 2024 Jun; 29(4):185-193. PubMed ID: 38568742
[TBL] [Abstract][Full Text] [Related]
20. NCAPH is upregulated in endometrial cancer and associated with poor clinicopathologic characteristics.
Qiu X; Gao Z; Shao J; Li H
Ann Hum Genet; 2020 Nov; 84(6):437-446. PubMed ID: 32628282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]